116 related articles for article (PubMed ID: 9590141)
1. Treatment of multifocal lymphoma of bone with intensified ProMACE-CytaBOM chemotherapy and involved field radiotherapy.
Rapoport AP; Constine LS; Packman CH; Rosier RN; O'Keefe R; Hicks DG; Rubin SJ; Rowe JM
Am J Hematol; 1998 May; 58(1):1-7. PubMed ID: 9590141
[TBL] [Abstract][Full Text] [Related]
2. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
[TBL] [Abstract][Full Text] [Related]
3. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Baldini L; Guffanti A; Gobbi P; Colombi M; Federico M; Avanzini P; Cavanna L; Pieresca C; Silingardi V; Maiolo AT
Cancer; 1997 Mar; 79(6):1234-40. PubMed ID: 9070503
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
[TBL] [Abstract][Full Text] [Related]
5. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
6. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
8. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas.
Fisher RI; Miller TP; Dana BW; Jones SE; Dahlberg S; Coltman CA
Semin Hematol; 1987 Apr; 24(2 Suppl 1):21-5. PubMed ID: 2438778
[TBL] [Abstract][Full Text] [Related]
9. Primary colorectal T-cell lymphoma.
Okada M; Maeda K; Suzumiya J; Hagimoto T; Wakamatsu S; Ohshima K; Kanda M; Sonoda T; Sakamoto A; Tamura K
J Gastroenterol; 2003; 38(4):376-84. PubMed ID: 12743779
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
[TBL] [Abstract][Full Text] [Related]
11. Primary lymphoma of bone in children: analysis of treatment results with adriamycin, prednisone, Oncovin (APO), and local radiation therapy.
Loeffler JS; Tarbell NJ; Kozakewich H; Cassady JR; Weinstein HJ
J Clin Oncol; 1986 Apr; 4(4):496-501. PubMed ID: 3958763
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
Gordon LI; Anderson J; Habermann TM; Winter JN; Glick J; Schilder RJ; Cassileth P
J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
[TBL] [Abstract][Full Text] [Related]
13. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
14. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
[TBL] [Abstract][Full Text] [Related]
15. [Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
Hou M; Li L; Qiu M; Yan X; Zhu J; Gou HF
Ai Zheng; 2005 Apr; 24(4):461-4. PubMed ID: 15820070
[TBL] [Abstract][Full Text] [Related]
16. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M
Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.
Witzig TE; Camoriano JK; Schroeder G; Kurtin PJ; Habermann TM
Leuk Lymphoma; 1998 Jan; 28(3-4):307-14. PubMed ID: 9517502
[TBL] [Abstract][Full Text] [Related]
20. Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Mannina D; Luminari S; Dondi A; Polimeno G; Baldini L; Stelitano C; Merli F; Dell'Olio M; Gobbi PG; Giglio G; Barbolini E; Brugiatelli M; Federico M
Leuk Lymphoma; 2010 Mar; 51(3):422-9. PubMed ID: 20038237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]